References

The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer.

10.1016/j.clon.2010.05.016 · 2010 · External reference

Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.

10.1002/cncr.34823 · 2023 · External reference

Tumor progression in waiting time for radiotherapy in head and neck cancer.

10.1016/j.radonc.2007.04.001 · 2007 · External reference

Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma: a narrative review.

10.1001/jamaoncol.2023.4042 · 2023 · External reference

Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus–associated oropharyngeal cancer.

10.1001/jamaoto.2023.1937 · 2023 · External reference

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

10.1200/jco.2004.05.178 · 2004 · External reference

Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial.

10.1200/jco.2018.77.7847 · 2018 · External reference

Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS): a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.

10.1038/s41416-022-01716-7 · 2022 · External reference

Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.

10.1038/s41418-024-01272-y · 2024 · External reference

Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma.

10.1158/1078-0432.ccr-24-0590 · 2024 · External reference

Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications.

10.1007/s11912-019-0799-x · 2019 · External reference

Abstract 4542: Analytical validation of the Signatera TM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay.

10.1158/1538-7445.am2018-4542 · 2018 · External reference

Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer.

10.1093/annonc/mdy281.004 · 2018 · External reference

Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence.

10.1158/1538-7445.sabcs18-p4-01-02 · 2019 · External reference

Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.

10.1016/j.oraloncology.2024.107002 · 2024 · External reference

Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance.

10.1158/1078-0432.ccr-23-1478 · 2023 · External reference

Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI.

10.1016/s0720-048x(99)00120-5 · 2000 · External reference

The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma.

10.1001/archoto.2011.181 · 2011 · External reference

Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT: systematic review and meta-analysis.

10.1177/0194599815621742 · 2016 · External reference

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.

10.3310/hta21170 · 2017 · External reference

12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers.

10.1016/j.oraloncology.2019.08.011 · 2019 · External reference

Contemporary imaging and reporting strategies for head and neck cancer: MRI, FDG PET/MRI, NI-RADS, and carcinoma of unknown primary—AJR expert panel narrative review.

10.2214/ajr.22.28120 · 2023 · External reference

Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer.

10.1002/hed.25425 · 2019 · External reference

Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer.

10.1186/s12967-020-02330-y · 2020 · External reference

Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.

10.1016/j.oraloncology.2024.106874 · 2024 · External reference

ctDNA as an adjunct to posttreatment PET for head and neck cancer recurrence risk assessment.

10.1002/ohn.760 · 2024 · External reference

Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis.

10.1200/po-25-00489 · 2025 · External reference

Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer.

10.1001/jamaoncol.2019.3616 · 2019 · External reference

Assessment of molecular relapse detection in early-stage breast cancer.

10.1001/jamaoncol.2019.1838 · 2019 · External reference

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.

10.1158/2159-8290.cd-17-0716 · 2017 · External reference

Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.

10.1200/jco.18.02052 · 2019 · External reference

Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer.

10.1158/1078-0432.ccr-21-0410 · 2021 · External reference

The Sinai Robotic Surgery Trial in HPV-related oropharyngeal squamous cell carcinoma (SIRS 2.0 trial): study protocol for a phase II non-randomized non-inferiority trial.

10.3389/fonc.2022.965578 · 2022 · External reference

Early disease recurrence following post-operative HPV ctDNA directed active surveillance in oropharyngeal carcinoma–outcomes of a prospective pilot study.

10.1016/j.ijrobp.2024.02.003 · 2024 · External reference

Postoperative human papilloma virus circulating tumor DNA guided adjuvant therapy for human papilloma virus-related oropharyngeal carcinoma (PATH study).

10.1016/j.ijrobp.2025.09.044 · 2026 · External reference

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.

10.1056/nejmoa2200075 · 2022 · External reference

Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis.

10.3389/fonc.2022.943253 · 2022 · External reference

Unresolved reference

External reference